Eli Lilly (LLY) Initial Phase 3 Data Looks Competitive Versus Dupixent - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Buy rating and $285.00 price target on Eli Lilly (NYSE: LLY) noting that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
